Overall survival of relapsed and refractory multiple myeloma patients after adjusting for crossover in the MM-003 trial for pomalidomide plus low-dose dexamethasone

被引：21

作者：

Morgan, Gareth ^{[1
]}

Palumbo, Antonio ^{[2
]}

Dhanasiri, Sujith ^{[3
]}

Lee, Dawn ^{[4
]}

Weisel, Katja ^{[5
]}

Facon, Thierry ^{[6
]}

Delforge, Michel ^{[7
]}

Oriol, Albert ^{[8
]}

Zaki, Mohamed ^{[9
]}

Yu, Xin ^{[9
]}

Sternas, Lars ^{[9
]}

Jacques, Christian ^{[9
]}

Akehurst, Ron ^{[4
,10
]}

Offner, Fritz ^{[11
]}

Dimopoulos, Meletios A. ^{[12
]}

机构：

[1] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA

[2] Via Univ Torino, Turin, Italy

[3] Celgene Ltd, London, England

[4] Bres Med, Sheffield, S Yorkshire, England

[5] Univ Tubingen, Tubingen, Germany

[6] CHU Lille, Serv Malad Sang, F-59037 Lille, France

[7] Univ Hosp Leuven, Leuven, Belgium

[8] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

[9] Celgene Corp, Summit, NJ USA

[10] Univ Sheffield, Sheffield, S Yorkshire, England

[11] Univ Ziekenhuis Gent, Ghent, Belgium

[12] Univ Athens, Alexandra Hosp, Sch Med, Athens 11528, Greece

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2015年 / 168卷 / 06期

关键词：

multiple myeloma; pomalidomide; survival; crossover; bias;

D O I：

10.1111/bjh.13227

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In the phase III MM-003 trial, pomalidomide plus low-dose dexamethasone (POM+LoDEX) improved overall survival (OS) versus high-dose dexamethasone (HiDEX) in 455 patients with relapsed and refractory multiple myeloma (RRMM) after treatment with bortezomib and lenalidomide. Here, a two-stage Weibull method was used to adjust for the crossover of patients in the HiDEX arm to pomalidomide-based therapy. The adjusted difference in median OS between patients in the POM+LoDEX and HiDEX arms was 70months (127 vs. 57months, respectively). These findings provide important evidence for understanding the clinical efficacy of pomalidomide on OS benefits seen in RRMM patients.

引用

页码：820 / 823

页数：4

共 12 条

[1]

[Anonymous], 2012, Health Outcome Res Med, DOI DOI 10.1016/J.EHRM.2012.01.001

[2] Double Refractory Myeloma: Analysis Of Clinical Outcomes and Medical-Resource Utilisation In a Single Centre [J].

Gooding, Sarah ;

Lau, I-Jun ;

Sheikh, Mimi ;

Roberts, Pamela ;

Wong, Julia ;

Dickens, Emmy ;

Elvidge, Jamie ;

Lee, Dawn ;

Ramasamy, Karthik .

BLOOD, 2013, 122 (21)

[3] Adjusting for Patient Crossover in Clinical Trials Using External Data: A Case Study of Lenalidomide for Advanced Multiple Myeloma [J].

Ishak, K. Jack ;

Caro, J. Jaime ;

Drayson, Mark T. ;

Dimopoulos, Meletios ;

Weber, Donna ;

Augustson, Bradley ;

Child, J. Anthony ;

Knight, Robert ;

Iqbal, Gulnaz ;

Dunn, Janet ;

Shearer, Arran ;

Morgan, Gareth .

VALUE IN HEALTH, 2011, 14 (05) :672-678

[4] Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study [J].

Kumar, S. K. ;

Lee, J. H. ;

Lahuerta, J. J. ;

Morgan, G. ;

Richardson, P. G. ;

Crowley, J. ;

Haessler, J. ;

Feather, J. ;

Hoering, A. ;

Moreau, P. ;

LeLeu, X. ;

Hulin, C. ;

Klein, S. K. ;

Sonneveld, P. ;

Siegel, D. ;

Blade, J. ;

Goldschmidt, H. ;

Jagannath, S. ;

Miguel, J. S. ;

Orlowski, R. ;

Palumbo, A. ;

Sezer, O. ;

Rajkumar, S. V. ;

Durie, B. G. M. .

LEUKEMIA, 2012, 26 (01) :149-157

[5] Clinical course of patients with relapsed multiple myeloma [J].

Kumar, SK ;

Therneau, TM ;

Gertz, MA ;

Lacy, MQ ;

Dispenzieri, A ;

Rajkumar, SV ;

Fonseca, R ;

Witzig, TE ;

Lust, JA ;

Larson, DR ;

Kyle, RA ;

Greipp, PR .

MAYO CLINIC PROCEEDINGS, 2004, 79 (07) :867-874

[6]

Latimer N. R., 2013, 1306 HEDS

[7]

Maciorowski G., 2014, SPOTTED EAGLE VANISH

[8] Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study [J].

Morden, James P. ;

Lambert, Paul C. ;

Latimer, Nicholas ;

Abrams, Keith R. ;

Wailoo, Allan J. .

BMC MEDICAL RESEARCH METHODOLOGY, 2011, 11

[9] Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) for relapsed or refractory multiple myeloma (RRMM): Overall survival (OS) results of MM-003 after adjustment for Res crossover. [J].

Morgan, Gareth J. ;

San Miguel, Jesus ;

Dhanasiri, Sujith ;

Lee, Dawn ;

Palumbo, Antonio ;

Facon, Thierry ;

Zaki, Mohamed H. ;

Yu, Xin ;

Sternas, Lars Axel ;

Jacques, Christian ;

Weisel, Katja C. ;

Offner, Fritz ;

Dimopoulos, Meletios A. .

JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)

[10] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial [J].

San Miguel, Jesus ;

Weisel, Katja ;

Moreau, Philippe ;

Lacy, Martha ;

Song, Kevin ;

Delforge, Michel ;

Karlin, Lionel ;

Goldschmidt, Hartmut ;

Banos, Anne ;

Oriol, Albert ;

Alegre, Adrian ;

Chen, Christine ;

Cavo, Michele ;

Garderet, Laurent ;

Ivanova, Valentina ;

Martinez-Lopez, Joaquin ;

Belch, Andrew ;

Palumbo, Antonio ;

Schey, Stephen ;

Sonneveld, Pieter ;

Yu, Xin ;

Sternas, Lars ;

Jacques, Christian ;

Zaki, Mohamed ;

Dimopoulos, Meletios .

LANCET ONCOLOGY, 2013, 14 (11) :1055-1066

← 1 2 →